Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Patients by Polymerase Chain Reactions

  • C. R. Bartram
  • S. Yokota
  • A. Biondi
  • J. W. G. Janssen
  • T. E. Hansen-Hagge
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Significant progress has been achieved in the treatment of acute lymphoblastic leukemia (ALL) by the introduction of modern chemotherapeutic strategies [1]. However, disease relapse following successful remission induction still poses a major clinical challenge. The quantity and kinetic behavior of residual leukemic cells remains largely enigmatic due to the limitation of most currently available techniques to identify less than 1%–5% neoplastic cells in the population being examined [2]. The use of double-color immunofluorescence has markedly improved the sensitivity with which persisting disease can be detected in distinct leukemias characterized by phenotypic features that are extremely rare or absent on normal hematopoietic counterparts [3]. More recently the development of polymerase chain reaction (PCR) strategies has opened a new era in the analysis of minimal residual disease by allowing the identification of neoplastic cells at a 10−4 to 10−6 level [4]. In the following we will summarize our experience with the application of PCR techniques in monitoring ALL patients during the course of the disease.

Keywords

Leukemia Recombination Agarose Bromide Oligomer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin R, Gale RP (1989) Acute lymphoblastic leukemia: recent advantages in biology and therapy. Blood 73: 2051–2066PubMedGoogle Scholar
  2. 2.
    Hagenbeek A, Löwenberg B (eds) (1986) Minimal residual disease in acute leukemia. Nijhoff, DordrechtGoogle Scholar
  3. 3.
    Campana D, Coustan-Smith E, Janossy G (1990) The immunologic detection of residual disease in acute leukemia. Blood 76: 163–171PubMedGoogle Scholar
  4. 4.
    Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487–491PubMedCrossRefGoogle Scholar
  5. 5.
    Hansen-flagge TE, Yokota S, Bartram CR (1989) Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor ô chain sequences. Blood 74: 1762–1767Google Scholar
  6. 6.
    D’Auriol L, Maclntyre E, Galibert F, Sigaux F (1989) In vitro amplification of Teell y gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. Leukemia 3: 155–158PubMedGoogle Scholar
  7. 7.
    Yamada M, Hudson S, Tournay O. Bitten-bender S, Shane SS, Lange B, Tsujimoto Y, Caton AJ, Rovera G (1989) Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using thirdcomplementarity-determining region (CDR-III) specific probes. Proc Natl Acad Sci USA 15. 86: 5123–5127Google Scholar
  8. 8.
    Yokota S, Hansen-Hagge TE, Bartram CR (1991) T-cell receptor S gene recombination in common acute lymphoblastic leukemia: preferential usage of VS, and frequent involvement of the Ja cluster. Blood 77: 141–148PubMedGoogle Scholar
  9. 9.
    Yokota S, Hansen-Hagge TE, Ludwig WD, Reiter A, Raghavachar A, Kleihauer E, Bartram CR (1991) The use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77: 331–339PubMedGoogle Scholar
  10. 10.
    Campana D, Yokota S, Coustan-Smith E, Hansen-Hagge TE, Janossy G, Bartram CR (1990) The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study. Leukemia 4: 609–614PubMedGoogle Scholar
  11. 11.
    Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G (1990) Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 323: 488–495CrossRefGoogle Scholar
  12. 12.
    Macintyre EA, d’Auriol L, Duparc N, Leverger G, Galibert F, Sigaux F (1990) Use of oligonucleotide probes directed against Teell antigen receptor gamma delta variable(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. J Clin Invest 86: 2125–2135PubMedCrossRefGoogle Scholar
  13. 13.
    Raghavachar A,Thiel E, Bartram CR (1987) Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 70: 1079–1083Google Scholar
  14. 14.
    Martens ACM, Schultz FW, Hagenbeek A (1987) Nonhomogenous distribution of leukemia in the bone marrow during minimal residual disease. Blood 70: 1073–1078PubMedGoogle Scholar
  15. 15.
    Kurzrock R, Gutterman JU,Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990–998Google Scholar
  16. 16.
    Maurer J, Janssen JWG, Thiel E, van Den-deren J, Ludwig WD, Aydemir Ü, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR (1991) Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by polymerase chain reaction: frequency and clinical relevance. Lancet 337: 1055–1058PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • C. R. Bartram
    • 1
  • S. Yokota
    • 1
  • A. Biondi
    • 2
  • J. W. G. Janssen
    • 1
  • T. E. Hansen-Hagge
    • 1
  1. 1.Section of Molecular Biology, Department of Pediatrics IIUniversity of UlmUlmGermany
  2. 2.Department of Pediatrics, Ospedale S. Gerado (Monza)University of MilanItaly

Personalised recommendations